Search Results Search Sort by RelevanceMost Recent Case and Commentary Dec 2020 Should a Patient Who Is Pregnant and Brain Dead Receive Life Support, Despite Objection From Her Appointed Surrogate? Daniel Sperling, SJD Lack of ethical, legal, and clinical consensus about best practice sometimes combines with a poor clinical evidence base. AMA J Ethics. 2020;22(12):E1004-1009. doi: 10.1001/amajethics.2020.1004. Medicine and Society Jul 2021 How Pharmaceuticals Mask Health and Social Inequity Enrico G. Castillo, MD, MSHPM and Joel Tupper Braslow, MD, PhD Pharmaceuticals make symptoms and biological drug targets more visible but can render individual and community suffering less visible. AMA J Ethics. 2021;23(7):E542-549. doi: 10.1001/amajethics.2021.542. History of Medicine Nov 2018 Ads and Labels From Early 20th-Century Health Fraud Promotions Amber Dushman, MA, MLIS In the 1910s, the American Medical Association fought quackery promoted in pamphlets for drugs and treatments for everything from teething to epilepsy. AMA J Ethics. 2018;20(11):E1082-1093. doi: 10.1001/amajethics.2018.1082. Case and Commentary Mar 2019 Should Hospital Emergency Departments Be Used as Revenue Streams Despite Needs to Curb Overutilization? Alex Myers, Aaron Cain, Berkeley Franz, PhD, and Daniel Skinner, PhD Using emergency departments as revenue streams could violate ethical and legal standards about hospitals’ roles in communities. AMA J Ethics. 2019;21(3):E207-214. doi: 10.1001/amajethics.2019.207. Case and Commentary Mar 2019 What Should Be the Scope of a Health Network’s Obligation to Respond After a Hospital Closure? George M. Holmes, PhD and Sharita R. Thomas, MPP Since clinics are economic hubs in some communities, consequences of a clinic closing or moving are numerous. AMA J Ethics. 2019;21(3):E215-222. doi: 10.1001/amajethics.2019.215. Policy Forum Jul 2016 Protecting Pharmaceutical Patents and Test Data: How the Trans-Pacific Partnership Agreement Could Affect Access to Medicines in the US and Abroad Jing Luo, MD and Aaron S. Kesselheim, MD, JD, MPH The Trans-Pacific Partnership Agreement could affect low-income patients’ access to medicines in signatory countries by reducing generic competition. AMA J Ethics. 2016;18(7):727-735. doi: 10.1001/journalofethics.2016.18.7.pfor1-1607. Podcast May 2019 Ethics Talk: When and How Should ECMO Be Initiated and Removed? When should ECMO be started and stopped? This month’s Ethics Talk explores ethical challenges of ECMO use in end-of-life care. Case and Commentary Oct 2019 How Should Decision Science Inform Scarce Blood Product Allocation? Eric Kersjes, MD and Lauren B. Smith, MD Decision aids could help clinicians know when to request ethics consultation or re-evaluate blood product usage in a specific patient care situation. AMA J Ethics. 2019;21(10):E852-857. doi: 10.1001/amajethics.2019.852. Case and Commentary Jul 2019 Should Dialysis Be Stopped for an Unrepresented Patient With Metastatic Cancer? Adira Hulkower, JD, MS, Sarah Garijo-Garde, and Lauren S. Flicker, JD, MBE Legal inconsistencies and variation in end-of-life options generate disparities in care for unrepresented patients. AMA J Ethics. 2019;21(7):E575-581. doi: 10.1001/amajethics.2019.575. AMA Code Says Jul 2019 AMA Code of Medical Ethics’ Opinions Related to Unrepresented Patients Danielle Hahn Chaet, MSB The AMA Code of Medical Ethics discusses situations in which a surrogate is needed but not available to make health care decisions for a patient. AMA J Ethics. 2019;21(7):E600-602. doi: 10.1001/amajethics.2019.600. Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Next page Next › Last page Last »
Case and Commentary Dec 2020 Should a Patient Who Is Pregnant and Brain Dead Receive Life Support, Despite Objection From Her Appointed Surrogate? Daniel Sperling, SJD Lack of ethical, legal, and clinical consensus about best practice sometimes combines with a poor clinical evidence base. AMA J Ethics. 2020;22(12):E1004-1009. doi: 10.1001/amajethics.2020.1004.
Medicine and Society Jul 2021 How Pharmaceuticals Mask Health and Social Inequity Enrico G. Castillo, MD, MSHPM and Joel Tupper Braslow, MD, PhD Pharmaceuticals make symptoms and biological drug targets more visible but can render individual and community suffering less visible. AMA J Ethics. 2021;23(7):E542-549. doi: 10.1001/amajethics.2021.542.
History of Medicine Nov 2018 Ads and Labels From Early 20th-Century Health Fraud Promotions Amber Dushman, MA, MLIS In the 1910s, the American Medical Association fought quackery promoted in pamphlets for drugs and treatments for everything from teething to epilepsy. AMA J Ethics. 2018;20(11):E1082-1093. doi: 10.1001/amajethics.2018.1082.
Case and Commentary Mar 2019 Should Hospital Emergency Departments Be Used as Revenue Streams Despite Needs to Curb Overutilization? Alex Myers, Aaron Cain, Berkeley Franz, PhD, and Daniel Skinner, PhD Using emergency departments as revenue streams could violate ethical and legal standards about hospitals’ roles in communities. AMA J Ethics. 2019;21(3):E207-214. doi: 10.1001/amajethics.2019.207.
Case and Commentary Mar 2019 What Should Be the Scope of a Health Network’s Obligation to Respond After a Hospital Closure? George M. Holmes, PhD and Sharita R. Thomas, MPP Since clinics are economic hubs in some communities, consequences of a clinic closing or moving are numerous. AMA J Ethics. 2019;21(3):E215-222. doi: 10.1001/amajethics.2019.215.
Policy Forum Jul 2016 Protecting Pharmaceutical Patents and Test Data: How the Trans-Pacific Partnership Agreement Could Affect Access to Medicines in the US and Abroad Jing Luo, MD and Aaron S. Kesselheim, MD, JD, MPH The Trans-Pacific Partnership Agreement could affect low-income patients’ access to medicines in signatory countries by reducing generic competition. AMA J Ethics. 2016;18(7):727-735. doi: 10.1001/journalofethics.2016.18.7.pfor1-1607.
Podcast May 2019 Ethics Talk: When and How Should ECMO Be Initiated and Removed? When should ECMO be started and stopped? This month’s Ethics Talk explores ethical challenges of ECMO use in end-of-life care.
Case and Commentary Oct 2019 How Should Decision Science Inform Scarce Blood Product Allocation? Eric Kersjes, MD and Lauren B. Smith, MD Decision aids could help clinicians know when to request ethics consultation or re-evaluate blood product usage in a specific patient care situation. AMA J Ethics. 2019;21(10):E852-857. doi: 10.1001/amajethics.2019.852.
Case and Commentary Jul 2019 Should Dialysis Be Stopped for an Unrepresented Patient With Metastatic Cancer? Adira Hulkower, JD, MS, Sarah Garijo-Garde, and Lauren S. Flicker, JD, MBE Legal inconsistencies and variation in end-of-life options generate disparities in care for unrepresented patients. AMA J Ethics. 2019;21(7):E575-581. doi: 10.1001/amajethics.2019.575.
AMA Code Says Jul 2019 AMA Code of Medical Ethics’ Opinions Related to Unrepresented Patients Danielle Hahn Chaet, MSB The AMA Code of Medical Ethics discusses situations in which a surrogate is needed but not available to make health care decisions for a patient. AMA J Ethics. 2019;21(7):E600-602. doi: 10.1001/amajethics.2019.600.